BioStock: SynAct Pharma ready for phase IIb and uplisting

Recently, SynAct Pharma announced that they have submitted a Clinical Trial Application to initiate EXPAND, a phase IIb study with AP1189 in newly diagnosed patients with rheumatoid arthritis. The aim is to confirm the encouraging phase IIa results and to identify AP1189’s full efficacy potential. The company was recently also approved for listing on Nasdaq Stockholm Main Market with an expected first day of trading on July 12. BioStock got in touch with SynAct Pharma’s CEO Jeppe Øvlesen and CSO Thomas Jonassen.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/07/synact-pharma-ready-for-phase-iib-and-uplisting/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se